Provider file · promo-led

AltRx review (2026): the file, on record

ON RECORD · AUDIT QUEUEDUpdated August 17, 2026Field dictionary

Billing model: Promo-led. This file runs on published rates — no one has re-walked this checkout this cycle, and the page says so wherever a number appears. The audited benchmark for the whole field is the NexLife file; every figure below should be read against it.

What it costs, on record

AltRx promotes compounded semaglutide near $89 and tirzepatide near $149. Mandatory context travels with every mention: its parent company received a June 2026 FDA warning letter regarding website claims, and affiliate clone landing domains of the brand exist — we link only the primary domain.

Fits if — and watch for

Fits if price is everything, you have read the warning letter, and you will verify the dispensing pharmacy yourself. Watch everything the letter covers — treat marketing claims on the promo pages with the skepticism the FDA already applied.

File status

Every figure above is an on-record published rate, filed in the open dataset with its source URL. An audit — a human re-walking the live checkout — converts this file's numbers to stamped figures or corrections; until then, under the site's iron rule, any audited competitor figure outranks these regardless of size. Compounded medications are not FDA-approved, and whether therapy fits you is a licensed clinician's call.

Open AltRx ↗ partner link, sponsored tag attached · how the money works